Media stories about Check Cap (NASDAQ:CHEK) have trended somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive media coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Check Cap earned a coverage optimism score of 0.21 on Accern’s scale. Accern also assigned headlines about the medical research company an impact score of 45.1457036269401 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

These are some of the news headlines that may have impacted Accern Sentiment’s scoring:

Shares of CHEK stock traded down $0.04 during trading hours on Friday, hitting $3.98. 87,200 shares of the company’s stock traded hands, compared to its average volume of 332,337. Check Cap has a 12 month low of $3.08 and a 12 month high of $24.00.

Check Cap (NASDAQ:CHEK) last released its quarterly earnings results on Friday, August 10th. The medical research company reported ($0.70) earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.82) by $0.12. research analysts predict that Check Cap will post -2.6 EPS for the current year.

Several equities analysts have recently issued reports on CHEK shares. HC Wainwright set a $14.00 price target on shares of Check Cap and gave the company a “buy” rating in a research note on Wednesday, August 1st. Zacks Investment Research downgraded shares of Check Cap from a “buy” rating to a “hold” rating in a research note on Tuesday, July 24th.

About Check Cap

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based system that utilizes low-dose X-rays for screening of the colon to detect polyps, masses, and colorectal cancers in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule, which is designed to measure, collect, and transmit structural information; C-Scan Track, a biocompatible unit worn on the patient's back for capsule control, tracking, and data recording; and C-Scan View, a personal computer-based software package, which is designed to retrieve and process clinical data from the C-Scan Track, and to reconstruct and produce 3D visualization of the colon's inner surface.

Further Reading: Find a Trading Strategy That Works

Insider Buying and Selling by Quarter for Check Cap (NASDAQ:CHEK)

Receive News & Ratings for Check Cap Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Check Cap and related companies with's FREE daily email newsletter.